Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017

Mult Scler Relat Disord. 2017 Oct:17:177-178. doi: 10.1016/j.msard.2017.08.001. Epub 2017 Aug 9.

Authors

Katja Thomas¹, Tjalf Ziemssen²

Affiliations

¹ Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Germany.
² Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Germany. Electronic address: Tjalf.Ziemssen@uniklinikum-dresden.de.

PMID: 29055453
DOI: 10.1016/j.msard.2017.08.001

No abstract available

Publication types

Letter
Comment

MeSH terms

Alemtuzumab*
Antibodies, Monoclonal, Humanized
Humans
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting

Substances

Antibodies, Monoclonal, Humanized
Alemtuzumab